ReviewInternational journal of molecular sciences2024
The Underlying Molecular Mechanisms of the Placenta Accreta Spectrum: A Narrative Review.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The pro-inflammatory cytokines IFN-α and TNF-α inhibit organoid-derived extravillous trophoblast invasion.iScience · 2026Article
- The quintessential high-risk profile: advanced management strategies for placenta accreta spectrum in patients with advanced maternal age and IVF conception.BMC pregnancy and childbirth · 2026Review
- Cesarean Scar Implantation in the Evolution of Placenta Accreta Spectrum: Implications for Recognition and Clinical Management.O&G open · 2026Review
- Clinical insights into placenta accreta spectrum: a comprehensive review.Obstetrics & gynecology science · 2026Review
- Trophoblast invasion biology: from normal implantation to accreta spectrum and choriocarcinoma.Vascular biology (Bristol, England) · 2026Review
- Pathophysiology and Management of Placenta Accreta Spectrum.Journal of developmental biology · 2025Review
- NFĸB and its inhibitors in preeclampsia: mechanisms and potential interventions.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Associations of First-Trimester Screening Markers and Hematological Indices with Placenta Accreta Spectrum in Pregnancies Complicated by Placenta Previa.Biomedicines · 2025Article
- Universal First-Trimester Screening Biomarkers for Diagnosis of Preeclampsia and Placenta Accreta Spectrum.Biomolecules · 2025Article
- Decreased plasma APOA1 levels are associated with increased severity of placenta accreta spectrum disorders: a nested case-control study.Frontiers in endocrinology · 2025Article
- Construction of SGA prediction model based on multi-dimensional indicators in the second trimester of pregnancy: integrating parturient characteristics, serum markers and ultrasound parameters.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Placenta accreta spectrum (PAS) disorders are characterized by abnormal trophoblastic invasion into the myometrium, leading to significant maternal health risks. PAS includes placenta accreta (invasion < 50% of the myometrium), increta (invasion > 50%), and percreta (invasion through the entire myometrium). The condition is most associated with previous cesarean deliveries and increases in chance with the number of prior cesarians. The increasing global cesarean rates heighten the importance of early PAS diagnosis and management. This review explores genetic expression and key regulatory processes, such as apoptosis, cell proliferation, invasion, and inflammation, focusing on signaling pathways, genetic expression, biomarkers, and non-coding RNAs involved in trophoblastic invasion. It compiles the recent scientific literature (2014-2024) from the Scopus, PubMed, Google Scholar, and Web of Science databases. Identifying new biomarkers like AFP, sFlt-1, β-hCG, PlGF, and PAPP-A aids in early detection and management. Understanding genetic expression and non-coding RNAs is crucial for unraveling PAS complexities. In addition, aberrant signaling pathways like Notch, PI3K/Akt, STAT3, and TGF-β offer potential therapeutic targets to modulate trophoblastic invasion. This review underscores the need for interdisciplinary care, early diagnosis, and ongoing research into PAS biomarkers and molecular mechanisms to improve prognosis and quality of life for affected women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.